Page 41 - CASA Bulletin of Anesthesiology 2022, Vol 9, No 1 (1)
P. 41

Vol. 9, No 1, 2022




               参考文献

               1. Nicole Monnier，et al. Presence of two different genetic traits in malignant hyperthermia families: implication
                  for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology. 2002
                  Nov;97(5):1067-74.
               2. Taffarel P，et a1. Malignant hyperthermia syndrome：Case report．Arch Argent Pediatr. 2015 Apr;
                  113(2):e113-6.
               3. Ibarra M CA, et al. Malignant hyperthermia in Japan: Mutation screening of the entire ryanodine receptor type 1
                  gene coding region by direct sequencing. Anesthesiology. 2006 Jun; 104(6):1146-54.
               4. Rosenberg H, et al. Malignant hyperthermia. Orphanet J Rare Dis 2007; 2:21.
               5. Wang Y L，et al. Clinical features and diagnosis for Chinese cases with malignant hyperthermia: a case cluster
                  from 2005 to 2007．Chin Med J (Engl). 2010 May; 123(10):1241-5.
               6. Schneiderbanger D, et al. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk
                  Manag. 2014 May;10:355-62.
               7. J F Payen, et al. Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a
                  combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy. Anesthesiology.
                  1993 May;78(5):848-55.
               8. Urwyler A, et al. Ryanodine receptor gene (RYR1) mutations for diagnosing susceptibility to malignant
                  hyperthermia. Acta Anaesthesiol Scand. 2003 Apr;47(4):492.
               9. Henry Rosenberg. Mining for mutations in malignant hyperthermia. Anesth Analg. 2011 Nov;113(5):975-6.
               10. Brandom B W, et al. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible
                  population of the United States. Anesth Analg. 2013 May;116(5):1078-1086.
               11. Klingler W, et al. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-
                  centre study. Orphanet J Rare Dis .2014 Jan 16;9:8.










               吴勇: 博士、教授级高工，宁波海尔施基因科技有限公司首席技术官。中国医药生物技术协会生物诊断技术分会常务委
               员，浙江省特聘专家。北京大学生物学系理学学士；中科院上海植生所理学硕士；美国佛罗里达大学细胞及分子生物学
               博士。曾在美国贝克曼库尔特有限公司就职 8 年，主持开发出了多款分子检测产品。2011 年回国加盟海尔施集团主持
               开发分子诊断产品，至今已有 5 款多重基因产品获得 NMPA 三类注册证。共发表 SCI 论文 30 余篇，已获得中国专利局
               及美国专利局授权的发明专利 29 项。










                                                                                            P a g e  40 | 60
   36   37   38   39   40   41   42   43   44   45   46